Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Global Regulatory Systems01:28

Global Regulatory Systems

45
Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...
45
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

191
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
191
Drug Regulation01:25

Drug Regulation

1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Legal Guidelines for Documentation01:06

Legal Guidelines for Documentation

1.3K
The legal guidelines for nursing documentation are essential for ensuring accurate, professional, and ethical recording of patient care. The guidelines are discussed here:
1.3K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

148
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
148
Pharmacovigilance01:19

Pharmacovigilance

908
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
908

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Pharmaceutical Year That Was, 2025.

Pharmaceutical medicine·2025
Same author

Author's Reply to Pongpirul: "The Pharmaceutical Year that was, 2024".

Pharmaceutical medicine·2024
Same author

The Pharmaceutical Year that was, 2024.

Pharmaceutical medicine·2024
Same author

The Pharmaceutical Year That Was, 2023.

Pharmaceutical medicine·2023
Same author

The Pharmaceutical Year that was, 2021.

Pharmaceutical medicine·2021
Same author

How well do Regulation 28 reports serve future public health and safety?

Medicine, science, and the law·2021
Same journal

Regulatory Considerations for Combined Drug-Device Studies in Europe: A Case Study Involving Bile Sampling.

Pharmaceutical medicine·2026
Same journal

Language as an Eligibility Criterion in Pediatric Study Protocols Conducted in Europe (2007-2024) Reported in the ClinicalTrials.gov Database.

Pharmaceutical medicine·2026
Same journal

A Framework for Standardising Toxicity Management Guidelines in Oncology Clinical Trials.

Pharmaceutical medicine·2026
Same journal

Correction: Paediatric Phase I/II Clinical Trial Assessments Under the New EU Clinical Trial Regulation: A Descriptive Analysis.

Pharmaceutical medicine·2026
Same journal

An Expert Consensus-Based Review of Considerations for Developing a Quality Management System Framework for Studies Utilising Secondary Data for Real-World Evidence Generation.

Pharmaceutical medicine·2026
Same journal

Optimising Formulations for Paediatric Patients with Inherited Metabolic Disorders: The Case Study of Levocarnitine.

Pharmaceutical medicine·2026
See all related articles

Related Experiment Video

Updated: Jul 25, 2025

Implementation of Portable Emissions Measurement Systems PEMS for the Real-driving Emissions RDE Regulation in Europe
09:34

Implementation of Portable Emissions Measurement Systems PEMS for the Real-driving Emissions RDE Regulation in Europe

Published on: December 4, 2016

28.2K

Where is European Regulation 536/2014 Taking Us?

Anthony W Fox1

  • 1Editor Emeritus, Pharmaceutical Medicine, London, UK. phm@adis.com.

Pharmaceutical Medicine
|June 23, 2023
PubMed
Summary
This summary is machine-generated.

The European Union's new clinical trial authorisation process (Regulation 536/2014) is legally inflexible and retains significant national authority, despite aiming for harmonisation. Experience shows it disadvantages multinational trials more than it helps.

More Related Videos

Perspectives on Neuroscience
00:26

Perspectives on Neuroscience

Published on: July 31, 2007

5.0K
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.4K

Related Experiment Videos

Last Updated: Jul 25, 2025

Implementation of Portable Emissions Measurement Systems PEMS for the Real-driving Emissions RDE Regulation in Europe
09:34

Implementation of Portable Emissions Measurement Systems PEMS for the Real-driving Emissions RDE Regulation in Europe

Published on: December 4, 2016

28.2K
Perspectives on Neuroscience
00:26

Perspectives on Neuroscience

Published on: July 31, 2007

5.0K
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.4K

Area of Science:

  • Clinical Trials
  • Regulatory Science
  • European Union Law

Background:

  • The European Regulation 536/2014 introduced a centralised clinical trial authorisation process.
  • This regulation replaced the older European Directive 2001/20.
  • A key aim was to streamline multinational trial applications through a single, harmonised authorisation.

Purpose of the Study:

  • To evaluate the practical implementation and impact of the centralised clinical trial authorisation process under Regulation 536/2014.
  • To assess the flexibility and effectiveness of the new regulation in comparison to the previous directive.
  • To identify disadvantages and areas for improvement in the European clinical trial authorisation system.

Main Methods:

  • Analysis of the legal framework of European Regulation 536/2014.
  • Review of the practical experience and outcomes of the centralised authorisation process since its implementation.
  • Comparative assessment of the new regulation against the previous European Directive 2001/20.

Main Results:

  • The Regulation 536/2014 exhibits significant legal and technical inflexibility.
  • National Competent Authorities (NCAs) retain substantial powers, limiting the intended harmonisation.
  • The process has shown disadvantages for multinational clinical trials, contrary to its primary justification.

Conclusions:

  • The current centralised clinical trial authorisation process lacks desired flexibility.
  • The retention of NCA powers undermines the goal of a truly harmonised single authorisation.
  • Future iterations should incorporate greater flexibility and potentially optional authorisation pathways for European clinical trials.